RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Cytokinetics Stock

Cytokinetics Liabilities 2024

Cytokinetics Liabilities

1.21 B USD

Ticker

CYTK

ISIN

US23282W6057

WKN

A1W1KK

In 2024, Cytokinetics's total liabilities amounted to 1.21 B USD, a 7.83% difference from the 1.12 B USD total liabilities in the previous year.

Cytokinetics Aktienanalyse

What does Cytokinetics do?

Cytokinetics Inc. is a biotechnology company that was founded in 1998 and is headquartered in South San Francisco, California. The company focuses on developing novel therapies for diseases of the nervous system, cardiovascular system, and muscles. Cytokinetics develops its drugs by identifying proteins and molecules that have potential for treating diseases. The company's business model is based on the development of therapies that target the improvement of muscle strength and function. Cytokinetics is known for its innovative drug classes such as myosin inhibitors and activators, as well as its novel drug CK-274. The company offers various products aimed at improving muscle strength and function, including CK-274, a myosin inhibitor currently in phase III development for the treatment of hypertrophic cardiomyopathy. Cytokinetics is also the developer of Omecamtiv Mecarbil, a myosin activator for the treatment of heart failure, and SMN2 splicing modulators for improving SMN protein synthesis in patients with spinal muscular atrophy. The company has established partnerships with leading pharmaceutical companies for the further development and commercialization of its drugs. With its innovative therapies and industry expertise, Cytokinetics has become one of the leading biotechnology companies in the United States focused on improving muscle strength and function. Cytokinetics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Cytokinetics's Liabilities

Cytokinetics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Cytokinetics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Cytokinetics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Cytokinetics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Cytokinetics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Cytokinetics stock

What is the level of liabilities of Cytokinetics this year?

Cytokinetics has a debt balance of 1.21 B USD this year.

What were the liabilities of Cytokinetics compared to the previous year?

The liabilities of Cytokinetics have increased by 7.83% increased compared to the previous year.

What are the consequences of high debt for investors of Cytokinetics?

High liabilities can pose a risk for investors of Cytokinetics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Cytokinetics?

Low liabilities mean that Cytokinetics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Cytokinetics affect the company?

An increase in liabilities of Cytokinetics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Cytokinetics affect the company?

A decrease in the liabilities of Cytokinetics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Cytokinetics?

Some factors that can influence the liabilities of Cytokinetics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Cytokinetics so important for investors?

The liabilities of Cytokinetics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Cytokinetics take to modify the liabilities?

To change its liabilities, Cytokinetics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Cytokinetics pay?

Over the past 12 months, Cytokinetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cytokinetics is expected to pay a dividend of 0 USD.

What is the dividend yield of Cytokinetics?

The current dividend yield of Cytokinetics is .

When does Cytokinetics pay dividends?

Cytokinetics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cytokinetics?

Cytokinetics paid dividends every year for the past 0 years.

What is the dividend of Cytokinetics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cytokinetics located?

Cytokinetics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cytokinetics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cytokinetics from 12/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Cytokinetics pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Cytokinetics in the year 2023?

In the year 2023, Cytokinetics distributed 0 USD as dividends.

In which currency does Cytokinetics pay out the dividend?

The dividends of Cytokinetics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Cytokinetics

Our stock analysis for Cytokinetics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cytokinetics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.